WASHINGTON (AP) - Consumer health advocates and a patent holder on a highly anticipated blood thinner from Eli Lilly want the Food and Drug Administration to halt its review of the drug, which they say may be unsafe at the suggested dose.
The FDA has been reviewing Lilly's prasugrel since January 2008. A company study showed the drug prevents more heart attacks than an older drug, but also causes more internal bleeding.
Consumer watchdog Public Citizen and a research professor who holds a patent on the drug contend that the dose used in that study led to the excess bleeding. They ask the agency to halt its review until new studies are completed.
Web Search powered by YAHOO!
|
LifestylesLifestyles
Consumer group wants halt on review of Lilly drug
WASHINGTON (AP) - Consumer health advocates and a patent holder on a highly anticipated blood thinner from Eli Lilly want the Food and Drug Administration to halt its review of the drug, which they say may be unsafe at the suggested dose.
By:
|
WNCT
Published: June 03, 2009
Published: June 03, 2009
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Eli Lilly,
Food And Drug Administration,
Health_Medical_Pharma,
Heart Attacks,
Research Professor,
Social Issues,
Washington
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/10/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement